EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Physiologically based pharmacokinetic modeling to predict human pharmacokinetics of a novel mithramycin analog for Ewing sarcoma

Kumar Kulldeep Niloy, Jamie Horn, Nazmul Hasan Bhuiyan, Suhas S Bhosale, Khaled A Shaaban, Thomas E Prisinzano, Jon S Thorson, Jurgen Rohr, Markos Leggas iD

Cancer Chemotherapy and Pharmacology · 12.08.2026 · 96 (1)

DOI: 10.1007/s00280-026-04935-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 12.08.2026. Verfasst von Kumar Kulldeep Niloy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Plicamycin, Models, Biological, Sarcoma, Ewing, Antibiotics, Antineoplastic. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlicamycinModels, BiologicalSarcoma, EwingAntibiotics, AntineoplasticHumansAnimalsMacaca fascicularisRatsMiceMaleFemale

Stichwörter der Autor:innen

Ewing sarcomaFirst-in-human dose predictionInterspecies scalingMithramycin analogPhysiologically based pharmacokinetic model

Substanzen

PlicamycinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
  • Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. mark.leggas@stjude.org.
  • Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA. mark.leggas@stjude.org.

ORCID-Profile: Markos Leggas

Förderung

  • NCATS NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • Center of Biomedical Research Excellence (COBRE) for Translational Chemical Biology (CTCB)
  • National Institute of Food and Agriculture (USDA-NIFACBGP)
  • Kentucky Medical Services Foundation Chair in Pharmacy
  • University of Kentucky College of Pharmacy
  • Markey Cancer Center, University of Kentucky

Zitieren

APA

Niloy, K. K., Horn, J., Bhuiyan, N. H., Bhosale, S. S., Shaaban, K. A., Prisinzano, T. E., Thorson, J. S., Rohr, J., & Leggas, M. (2026). Physiologically based pharmacokinetic modeling to predict human pharmacokinetics of a novel mithramycin analog for Ewing sarcoma. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04935-4

Vancouver

Niloy KK, Horn J, Bhuiyan NH, Bhosale SS, Shaaban KA, Prisinzano TE, et al. Physiologically based pharmacokinetic modeling to predict human pharmacokinetics of a novel mithramycin analog for Ewing sarcoma. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04935-4

BibTeX
@article{Niloy2026,
  author = {Niloy, Kumar Kulldeep and Horn, Jamie and Bhuiyan, Nazmul Hasan and Bhosale, Suhas S and Shaaban, Khaled A and Prisinzano, Thomas E and Thorson, Jon S and Rohr, Jurgen and Leggas, Markos},
  title = {Physiologically based pharmacokinetic modeling to predict human pharmacokinetics of a novel mithramycin analog for Ewing sarcoma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04935-4}
}
Kostenlos starten →